Table 1 Treatment schema for E. coli-asparaginase and PEG-asparaginase groups.

From: Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study

E. coli-asparaginase group		PEG-asparaginase group
Therapy	Dosage and days	Therapy	Dosage and days
Induction
Phase 1
Daunorubicin IV	60 mg/m² days 1, 8, 15, 22	Daunorubicin IV	60 mg/m² days 1, 8, 15, 22
Vincristine IV	1.4 mg/m² days 1, 8, 15, 22	Vincristine IV	1.4 mg/m² days 1, 8, 15, 22
E. coli-asparaginase IV	10000 IU qod days 2–24 (12 doses)	PEG-asparaginase IM	2000 IU/m² days 2, 16
Prednisone PO	60 mg/m² days 1–28	Prednisone PO	60 mg/m² days 1–28
Methotrexate IT	12.5 mg day 15	Methotrexate IT	12.5 mg day 15
Phase 2
Cyclophosphamide IV	650 mg/m² days 1, 15, 29	Cyclophosphamide IV	650 mg/m² days 1, 15, 29
Cytarabine IV	75 mg/m² days 1–4, 8–11, 15–18, 22–25	Cytarabine IV	75 mg/m² days 1–4, 8–11, 15–18, 22–25
6-mercaptopurine PO	6 mg/m² days 1–28	6-mercaptopurine PO	6 mg/m² days 1–28
Methotrexate IT	12.5 mg day 1, 8, 15, 22	Methotrexate IT	12.5 mg day 1, 8, 15, 22
Intensification
Methotrexate IV	3 g/m² days 1, 8, 22	Methotrexate IV	3 g/m² days 1, 8, 22
E. coli-asparaginase IV	10000 IU qod days 2–12 (6 doses)	PEG-asparaginase IM	2000 IU/m² day 2
Consolidation
Cycle 1
Cytarabine IV	75 mg/m² days 1–5	Cytarabine IV	75 mg/m² days 1–5
Etoposide IV	100 mg/m² days 1–5	Etoposide IV	100 mg/m² days 1–5
Vincristine IV	1.4 mg/m² days 1, 8, 15, 22	Vincristine IV	1.4 mg/m² days 1, 8, 15, 22
Dexamethasone PO	10 mg/m² days 1–28	Dexamethasone PO	10 mg/m² days 1–28
Cycle 2
Cytarabine IV	75 mg/m² days 1–5	Cytarabine IV	75 mg/m² days 1–5
Etoposide IV	100 mg/m² days 1–5	Etoposide IV	100 mg/m² days 1–5
Cycle 3
Daunorubicin IV	25 mg/m² days 1, 8, 15, 22	Daunorubicin IV	25 mg/m² days 1, 8, 15, 22
Cyclophosphamide IV	650 mg/m² day 29	Cyclophosphamide IV	650 mg/m² day 29
Cytarabine IV	75 mg/m² days 31–34, 38–41	Cytarabine IV	75 mg/m² days 31–34, 38–41
Thioguanine PO	60 mg/m² days 29–42	Thioguanine PO	60 mg/m² days 29–42
Cycle 4
Cytarabine IV	75 mg/m² days 1–5	Cytarabine IV	75 mg/m² days 1–5
Etoposide IV	100 mg/m² days 1–5	Etoposide IV	100 mg/m² days 1–5
CNS prophylaxis in consolidation: Cytarabine IT, 50 mg, was given weekly for 4 weeks, together with 2400 cGy cranial irradiation
Maintenance (2.5 years from the start of intensification therapy)
Vincristine IV	1.4 mg/m² day 1*every 3 months	Vincristine IV	1.4 mg/m² day 1* every 3 months
Prednisone PO	60 mg/m² days 1–5* every 3 months	Prednisone PO	60 mg/m² days 1–5* every 3 months
6-mercaptopurine PO	75 mg/m²*qd	6-mercaptopurine PO	75 mg/m²*qd
Methotrexate PO	20 mg/m²*qw	Methotrexate PO	20 mg/m²*qw
CNS prophylaxis in maintenance: Cytarabine IT, 50 mg, was given 3 months apart during maintenance therapy.

Abbreviations: E. coli-asparaginase, Escherichia coli asparaginase; PEG-asparaginase, polyethylene glycol-conjugated asparaginase; IV, intravenously; PO, oral; IM, intramuscular; IT, intrathecal.

Back to article page

Table 1 Treatment schema for E. coli-asparaginase and PEG-asparaginase groups.

Search

Quick links